Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.

Annals of hematology - 1 May 2023

Tosoni Luca, Fabbro Dora, Pizzano Umberto, Mullai Rikard, Morelli Gianluca, Franzoni Alessandra, Damante Giuseppe, Toffoletti Eleonora, Damiani Daniela, Fanin Renato, Tiribelli Mario

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Disease
Share to Janus Kinase 2
Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid

Share to Mutation

Share to Polycythemia Vera

Source

Identifiers

PMID: 36947213
DOI: 10.1007/s00277-023-05187-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.PMID 36947213Read ↗

Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.Semantic proximity Read ↗

JAK2V617F Exon-14 Mutation Driven Polycythemia Vera.Semantic proximity Read ↗

Existence of JAK2 mutation 19 years prior to the development of overt polycythemia vera.Semantic proximity Read ↗

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.Semantic proximity Read ↗

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.Semantic proximity Read ↗

After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.Semantic proximity Read ↗

Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.Semantic proximity Read ↗

Genetic Background of Polycythemia Vera.Semantic proximity Read ↗

JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.Semantic proximity Read ↗

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.Semantic proximity Read ↗

A Clue in JAK2: Masked Polycythemia Vera.Semantic proximity Read ↗

JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.